THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

Savient Pharmaceuticals, Inc. (SVNT)

4/12/2006 Proxy Information

Mr. Thompson was President and Chief Operating Officer of Savient Pharmaceuticals, Inc. from May 1999 through August 2000.

5/2/2005 Proxy Information

Mr. Kaplan is a partner of Fulbright & Jaworski L.L.P., which provided legal services to us during the first half of 2004.

Mr. Thompson was President and Chief Operating Officer of Savient Pharmaceuticals, Inc. from May 1999 through August 2000.

6/14/2004 Proxy Information

Virgil Thompson was President and Chief Operating Officer of Savient Pharmaceuticals, Inc. from May 1999 through August 2000

Carl E. Kaplan is a partner of Fulbright & Jaworski L.L.P., which provided legal services to us in 2003 and is providing legal services to us in 2004.

Jeremy Hayward-Surry served as the president and a director of Pall Corporation until August 2003 and November 2003, respectively. In 2003, Pall Corporation sold filters to Bio-Technology General (Israel) Ltd., one of our subsidiaries, through its Israeli distributor. The total amount of these sales was approximately $58,000. We believe that these purchases were made on terms no less favorable to us than would have been obtained from an unaffiliated third party.

In July 2003 we entered into an agreement with Marco Hi-Tech JV Ltd. (“Marco”) pursuant to which we agreed to invest an aggregate of $1,500,000 in Marco preferred stock, representing approximately 9% of Marco’s fully-diluted outstanding common stock, and acquired an option to exclusively market in the United States and Europe Huperzine-A, a product for the treatment of Alzheimer’s disease. The option is exercisable following completion of Phase II trials, which is expected to commence in June 2004 with partial funding by the National Institutes of Health. If we exercise the option, we are obligated to purchase an additional $3,000,000 of Marco preferred stock, representing an additional approximately 9% of Marco’s fully-diluted outstanding common stock, and to conduct and fund Phase III clinical trials and obtain regulatory approval. If regulatory approval of the product is obtained in Europe, we will also be required to pay an additional $1,500,000 to retain the exclusive rights in Europe following approval of Huperzine-A in a second major European country. We are obligated to use commercially reasonable efforts to commercialize the product following approval, and must pay Marco a royalty of 8% of net sales while patents are in effect and 4% of net sales thereafter. We invested $500,000 in Marco in July 2003, invested an additional $500,000 in March 2004 and are scheduled to make the remaining $500,000 investment in July 2004. David Tendler, one of our directors, owns common stock of Marco representing less than 1% of Marco’s fully-diluted outstanding common stock.

5/13/2003 Proxy Information

Mr. Hayward-Surry is the president and a director of Pall Corporation. In 2002, Pall Corporation sold filters to Bio-Technology General (Israel) Ltd., a subsidiary of the Company, through its Israeli distributor. The total amount of these sales was approximately $100,000. The Company believes that the aforementioned transaction was made on terms no less favorable to the Company than would have been obtained from an unaffiliated third party.